GentiBio
MA - CambridgeBiotechnology
Focus: GentiBio is a Cambridge-based biotech company focused on engineered regulatory T cell (Treg) therapies, targeting oncology and autoimmune/inflammatory diseases. The company is in early-stage clinical development with a novel cell therapy modality.
Profile data last refreshed 53m ago · AI intelligence enriched 2w ago
Open Jobs
0
About GentiBio
AI assessmentNot HiringNo open roles listed right now. Follow GentiBio to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from GentiBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
blood draw
Diabetes Mellitus, Type IClinical Trials (1)
NCT06860516HLA Demographics Study in Adults With Type 1 Diabetes
N/AHelp build intelligence for GentiBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.